314 related articles for article (PubMed ID: 27875388)
41. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
Simon JA; Reape KZ; Wininger S; Hait H
Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
[TBL] [Abstract][Full Text] [Related]
42. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
Tan O; Bradshaw K; Carr BR
Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
[TBL] [Abstract][Full Text] [Related]
43. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
44. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
45. Viewing symptoms associated with Vulvovaginal Atrophy (VVA)/Genitourinary syndrome of menopause (GSM) through the estro-androgenic lens - Cluster analysis of a web-based Italian survey among women over 40.
Nappi RE; Di Carlo C; Cucinella L; Gambacciani M
Maturitas; 2020 Oct; 140():72-79. PubMed ID: 32616374
[TBL] [Abstract][Full Text] [Related]
46. Primavera: A new therapeutical approach to vulvo-vaginal atrophy.
Amori P; Di Nardo V; Vitiello G; Franca K; Hercogova J; Wollina U; Daaboul F; Tchernev G; Lotti T
Dermatol Ther; 2018 Nov; 31(6):e12678. PubMed ID: 30411455
[TBL] [Abstract][Full Text] [Related]
47. Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy.
Ke Y; Bélanger A; Simard JN; Gonthier R; Martel C; Vaillancourt M; Labrie F
Menopause; 2018 Mar; 25(3):293-300. PubMed ID: 29206779
[TBL] [Abstract][Full Text] [Related]
48. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment.
Kao A; Binik YM; Amsel R; Funaro D; Leroux N; Khalifé S
J Sex Med; 2012 Aug; 9(8):2066-76. PubMed ID: 22621792
[TBL] [Abstract][Full Text] [Related]
49. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones.
Leiblum S; Bachmann G; Kemmann E; Colburn D; Swartzman L
JAMA; 1983 Apr 22-29; 249(16):2195-8. PubMed ID: 6834616
[TBL] [Abstract][Full Text] [Related]
50. DHEA and intracrinology at menopause, a positive choice for evolution of the human species.
Labrie F; Labrie C
Climacteric; 2013 Apr; 16(2):205-13. PubMed ID: 23126249
[TBL] [Abstract][Full Text] [Related]
51. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women.
Hirshman E; Merritt P; Wang CC; Wierman M; Budescu DV; Kohrt W; Templin JL; Bhasin S
Horm Behav; 2004 Feb; 45(2):144-55. PubMed ID: 15019802
[TBL] [Abstract][Full Text] [Related]
52. Testosterone and Vaginal Function.
Maseroli E; Vignozzi L
Sex Med Rev; 2020 Jul; 8(3):379-392. PubMed ID: 32434695
[TBL] [Abstract][Full Text] [Related]
53. Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG).
Labrie F; Luu-The V; Martel C; Chernomoretz A; Calvo E; Morissette J; Labrie C
J Steroid Biochem Mol Biol; 2006 Jul; 100(1-3):52-8. PubMed ID: 16797178
[TBL] [Abstract][Full Text] [Related]
54. Dehydroepiandrosterone, androgens and the mammary gland.
Labrie F
Gynecol Endocrinol; 2006 Mar; 22(3):118-30. PubMed ID: 16835073
[TBL] [Abstract][Full Text] [Related]
55. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women.
Labrie F; Bélanger A; Labrie C; Candas B; Cusan L; Gomez JL
J Steroid Biochem Mol Biol; 2007 Oct; 107(1-2):57-69. PubMed ID: 17627814
[TBL] [Abstract][Full Text] [Related]
56. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause.
Unkila M; Kari S; Yatkin E; Lammintausta R
J Steroid Biochem Mol Biol; 2013 Nov; 138():107-15. PubMed ID: 23665515
[TBL] [Abstract][Full Text] [Related]
57. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Bouchard C; Labrie F; Derogatis L; Girard G; Ayotte N; Gallagher J; Cusan L; Archer DF; Portman D; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
Horm Mol Biol Clin Investig; 2016 Mar; 25(3):181-90. PubMed ID: 26725467
[TBL] [Abstract][Full Text] [Related]
58. Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin.
Sourla A; Richard V; Labrie F; Labrie C
J Endocrinol; 2000 Aug; 166(2):455-62. PubMed ID: 10927635
[TBL] [Abstract][Full Text] [Related]
59. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Bérubé R; Bélanger P; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):897-906. PubMed ID: 19436226
[TBL] [Abstract][Full Text] [Related]
60. Progestational and androgenic substances tested on the highly proliferated vaginal epithelium of surgical castrates. II. Androgenic substances.
WIED GL; DEL SOL JR; DARGAN AM
Am J Obstet Gynecol; 1958 Feb; 75(2):289-300. PubMed ID: 13498072
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
